+

US20100279925A1 - Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract - Google Patents

Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract Download PDF

Info

Publication number
US20100279925A1
US20100279925A1 US11/993,264 US99326406A US2010279925A1 US 20100279925 A1 US20100279925 A1 US 20100279925A1 US 99326406 A US99326406 A US 99326406A US 2010279925 A1 US2010279925 A1 US 2010279925A1
Authority
US
United States
Prior art keywords
site
fviia
sifviia
inactivated fviia
inactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/993,264
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/993,264 priority Critical patent/US20100279925A1/en
Assigned to DRUGRECURE APS reassignment DRUGRECURE APS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UTTENTHAL, LARS OTTO
Publication of US20100279925A1 publication Critical patent/US20100279925A1/en
Assigned to HOIBERG A/S reassignment HOIBERG A/S CERTIFICATE OF DEBT Assignors: DRUGRECURE APS, PHARMAORIGIN APS
Assigned to HOIBERG A/S reassignment HOIBERG A/S CORRECTIVE CERTIFICATE OF DEBT AND AGREEMENT Assignors: DRUGRECURE APS, PHARMAORIGIN APS
Assigned to DRUGRECURE APS reassignment DRUGRECURE APS RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: HOIBERG A/S
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention provides methods to arrest acute, recurrent and chronic fibrin deposition in the airspaces of the respiratory tract, in particular the alveoli and/or bronchioli, in any disease associated with such deposition in children and adults.
  • diseases include inflammatory lung diseases such as acute lung injury (ALI), which may be related to direct or indirect pulmonary trauma, e.g.
  • ALI acute lung injury
  • VILI ventilator therapy
  • inflammatory conditions like autoimmune diseases, pancreatitis, aspiration pneumonitis, inhalation of toxic fumes, acute respiratory distress syndrome (ARDS), which is a more severe manifestation of ALI, infections such as sepsis, severe sepsis and septic shock; pneumonia of whatever cause; acute and chronic bronchoalveolar diseases, fibrosing alveolitis, bronchiolitis, cystic fibrosis and also diseases with severe airway hyperreactivity, e.g. bronchial asthma and drug induced lung insufficiency, e.g. following chemotherapy like bleomycin.
  • VILI ventilator therapy
  • inflammatory conditions like autoimmune diseases, pancreatitis, aspiration pneumonitis, inhalation of toxic fumes, acute respiratory distress syndrome (ARDS), which is a more severe manifestation of ALI, infections such as sepsis, severe sepsis and septic shock; pneumonia of whatever cause; acute and chronic bronchoalveolar diseases, fibro
  • an anticoagulants such as site-inactivated FVIIa (siFVIIa), whether these agents are derived from plasma or prepared by recombinant DNA technology, are administered intratracheally, intrabronchially, or to the alveolar space via airway administration.
  • siFVIIa site-inactivated FVIIa
  • the deposition of fibrin in the airspaces of the respiratory tract is a frequent complication of systemic inflammatory conditions such as those resulting from trauma, sepsis, severe sepsis and septic shock, drug induced ALI, ARDS or pneumonitis (e.g. due to metothrexate, bleomycin or sirolimus) (Amigues L, Klouche K, Massanet P, Gaillard N, Garrigue V, Beraud J J, Mourad G. Sirolimus-associated acute respiratory distress syndrome in a renal transplant recipient. Transplant Proc. 2005; 37:2830-1.) and ventilator-induced lung injury (VILI) (Macintyre N R.
  • VILI The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J. Med. 2000; 342:1301-1308.
  • TNF- ⁇ tumor necrosis factor alpha
  • IL-1 ⁇ interleukin 1-beta
  • IL-6 interleukin 6
  • IL-8 interleukin 8
  • Intravascular fibrin deposition and the release of pro-inflammatory cytokines in the airspaces of the lungs cause a tissue injury characterized by an increased permeability of the alveolar-capillary membrane with diffuse alveolar damage and the accumulation in the alveoli of edema fluid rich in plasma proteins, including the components of the blood coagulation system, and a reduction in surfactant production.
  • a fibrin-rich hyaline membrane is formed in the alveolar ducts and airspaces.
  • a massive infiltration of neutrophils and other inflammatory cells occurs, followed by organization of the exudates and fibrosis.
  • ALI/ARDS The pathogenesis of ALI/ARDS
  • Thorax 57:540-546 The clinical conditions corresponding to this pathology are called ALI or ARDS, differing only in that ARDS is more severe and characterized by greater hypoxemia such that the ratio of arterial P O2 to inspired oxygen fraction (Pa O2 /Fl O2 ) ⁇ 200 mmHg.
  • SIRS systemic inflammatory response syndrome
  • a similar sequence of pathological events occurs in pneumonias due to a variety of causes, including viral, bacterial and fungal agents, e.g. Pneumocystis carinii (PCP) pneumonia, bronchiolitis (e.g. secondary to viral pneumonitis and/or pulmonary graft-versus-host disease (GVHD)), leading also to alveolar exudates and fibrin deposition in those regions of the lung affected by the inflammatory process.
  • PCP Pneumocystis carinii
  • GVHD pulmonary graft-versus-host disease
  • tissue factor expressed locally on alveolar macrophage cells and on the epithelium, seems to have a pivotal role in the initiation of coagulation, while physiologic anticoagulation due to antithrombin and the protein C system is dysfunctional. It has been documented that the protein C system is markedly disrupted In patients with ALI/ARDS from both septic and non-septic causes and there is evidence of both circulatory and intra-alveolar derangements in the protein C pathway in ALI/ARDS (Ware L B et al., 2003: “Protein C and thrombomodulin in human acute lung injury”, Am J Physiol Lung Cell Mol Physiol 285:L514-L521).
  • the aim of the present invention is to improve the treatment of ALI, ARDS, pneumonia and inflammatory pulmonary diseases by addressing the local pulmonary activation of the coagulation system and the local deficiency of anticoagulatory mechanisms, by applying the relevant anticoagulants, or agents capable of blocking the local initiation of coagulation, by local administration into the airways.
  • a high local concentration of these agents can be achieved in the affected airways, so that extravascular fibrin deposition can be more effectively inhibited than by the systemic (intravenous) administration of the same agents, but avoiding or reducing systemic adverse effects.
  • the airway administration of these agents can be given alone or as a supplement to intravenous administration of the same or other agents. Because of the “cross-talk” between coagulation and inflammation, the airway administration of these agents is also expected to modulate local pulmonary inflammation, by reducing local thrombin activation and in certain cases also by direct anti-inflammatory action.
  • An aspect of the present invention relates to a method for reducing extravascular fibrin deposition in the airways, especially in the alveolar or bronchoalveolar spaces, In human subjects with inflammatory and/or infective pulmonary conditions that lead to such fibrin deposition, the method comprising the administration via the airway of anticoagulants, whether purified from plasma or obtained by recombinant DNA technology.
  • the present invention relates to the airway administration, by any appropriate method including, but not limited to, intratracheal, intrabronchial or intraalveolar administration, to a human subject inclusive of both adults and children, of purified or concentrated human site-inactivated FVIIa (siFVIIa), or derivatives thereof, however prepared, to prevent or reduce extravascular fibrin deposition in the airways, especially the alveolar or bronchoalveolar airspaces.
  • aFVIIa purified or concentrated human site-inactivated FVIIa
  • Such fibrin deposition may result from an acute condition, a recurrent condition or a chronic condition and may be due to a variety of causes, including but not limited to trauma, direct or indirect, inflammation or infection, due to drug induced fibrin deposition in airways and lung interstitium, congentinal diseases like Cystic fibrosis, or due to a combination of such possible causes.
  • the methods of the present invention will be useful in treating the alveolar fibrin deposition characteristic of ALI or ARDS arising in a large proportion of patients with sepsis of varying degrees, in patients with severe pneumonias, bronchiolitis obliterans and in fibrosing alveolitis.
  • Affinity the strength of binding between receptors and their ligands, for example between an antibody and its antigen.
  • Amino Acid Residue That part of the amino acid which is present in the polypeptide chain in which the amino acid is linked to other amino acids by peptide (amide) bonds.
  • the amino acid residues described herein are preferably in the “L” isomeric form.
  • the amino acid encompasses every amino acid such as L-amino acid, D-amino acid, alpha-amino acid, beta-amino acid, gamma-amino acid, natural amino acid and synthetic amino acid or the like, as long as the desired functional property is retained by the polypeptide.
  • natural or synthetic amino acids which have been modified.
  • NH 2 refers to the free amino group present at the amino terminus of a polypeptide.
  • COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. Standard polypeptide abbreviations for amino acid residues are used herein.
  • amino acid residue sequences represented herein by formulae have a left-to-right orientation in the conventional direction of amino terminus to carboxy terminus.
  • a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues or a covalent bond to an amino-terminal group such as NH 2 or acetyl or to a carboxy-terminal group such as COOH.
  • Modified amino acid an amino acid wherein an arbitrary group thereof is chemically modified.
  • a modified amino acid chemically modified at the alpha-carbon atom in an alpha-amino acid is preferable.
  • Polypeptide refers to a molecule comprising amino acid residues which do not contain linkages other than amide linkages between adjacent amino acid residues. The phrase peptide is used accordingly.
  • siFVIIa molecule is used herein to refer to any molecule capable of binding to and inhibiting directly or indirectly the coagulation factors IX, X and/or tissue factor (TF).
  • FVII is a vitamin K-dependent plasma protein synthesized in the liver and secreted into the blood as a single-chain glycoprotein with a molecular weight of 53 kDa (Broze & Majerus, J. Biol. Chem. 1980; 255:1242-1247).
  • the complete nucleotide and amino acid sequence for human factor VII are known, see U.S. Pat. No. 4,784,950.
  • factor VII is cleaved between residues 152 and 153 to yield factor VIIa.
  • FVII undergoes post-translational modifications, including vitamin K-dependent carboxylation resulting in ten gamma-carboxyglutamic acid residues in the N-terminal region of the molecule.
  • residue number 6, 7, 14, 16, 19, 20, 25, 26, 29 and 35 shown in SEQ ID NO: 1 are gamma-carboxyglutamic acids residues in the GIa domain important for FVII activity.
  • Other post-translational modifications include sugar moiety attachment at two naturally occurring N-glycosylation sites at position 145 and 322, respectively, and at two naturally occurring O-glycosylation sites at position 52 and 60, respectively.
  • SiFVIIa is intended to mean FVIIa having at least one modification, which modification substantially inhibits the ability of the modified FVIIa to activate factor IX and/or X.
  • Methods for assaying the functional activity of the siFVIIa molecules for use in the present invention include those described by FFR-rFVIIa analyses were performed by use of an ELISA.
  • the format of the assay was a sandwich ELISA, in which the catching antibody, adsorbed to the solid phase, was raised against FVIIa and reacted equally well with FFR-rFVIIa.
  • the plasma samples were diluted at a minimum five times before addition to the microtiter plate. This predilution was required to minimize blocking of binding sites on the solid phase with endogenous FVII/FVIIa. After incubation with sample and washing, a biotinylated monoclonal antibody specific for FFR-FVIIa was added.
  • the final steps of the analysis were addition of a conjugate of streptavidin and peroxidase, washing, and incubation with a substrate 5,5,5′,5′-tetramethylbenzidine.
  • the calibration curve ranged from 1 to 128 ng/ml; the lower LOQ was equal to the lowest calibrator 1 ng/ml.
  • the analysis could provide data as low as 5 ng/ml; responses lower than this limit were reported as ⁇ 5 ng/ml.
  • WO91/11514 Site-inactivated FVIIa, in which arginine 152 and/or isoleucine 153 of the natural FVIIa is/are modified has been described in WO91/11514. These amino acids are located at the activation site.
  • WO 96/12800 describes inactivation of FVIIa by a serine proteinase inhibitor, inactivation by carbamylation of FVIIa at the alpha-amino acid group 1153 has been described by Petersen et al., Eur J Biochem, 1999; 261:124-129.
  • the inactivated form is capable of competing with wild-type FVII or FVIIa for binding to tissue factor and inhibiting clotting activity.
  • the present invention further includes the use of recombinant or synthetically or transgenically produced human siFVIIa peptides.
  • the siFVIIa molecule is a homologue of FVIIa.
  • the human site-inactivated FVIIa that is intended to be administered according to the present invention comprises human site-inactivated FVIIa, or biologically active analogues of the same, whether prepared from plasma or recombinantly or transgenically or synthetically produced.
  • Recombinant site-inactivated FVIIa may incorporate modifications (e.g. amino acid substitutions and/or deletions and/or additions of heterologous amino acid sequences), which may result in analogues with enhanced biologic activity.
  • the siFVIIa can be produced using eukaryotic cell culture systems (e.g. human kidney 293, HEPG-2, SKHep, LLC-MK2, CHO or AV12 cells), transgenic animals, transgenic plants, or in vitro systems. In these systems, siFVIIa may be produced directly or by first producing FVII, which than is modified to become siFVIIa by, for example derivatisation.
  • siFVIIa Details of producing, purifying, activating, and formulating siFVIIa are known in the art and are described, for example, in WO 96/12800. Also, FVIIa genes and plasmids that can be used in these methods are described in U.S. Pat. No. 4,784,950 which is also incorporated by reference herein.
  • the siFVIIa molecule is an analogue of FVIIa.
  • An “FVIIa analogue” is defined as a molecule having one or more (such as 20 or fewer, for example 17 or fewer, such as 15 or fewer, for example 13 or fewer, such as 11 or fewer, for example 9 or fewer, such as 7 or fewer, for example 5 or fewer, such as 3 or fewer, for example 2 or fewer, such as 1 or fewer) amino acid substitutions, deletions, inversions, or additions relative to FVIIa and may include D-amino acid forms.
  • FVIIa analogues also have been described in U.S. Pat. No. 6,806,063, which hereby is incorporated by reference herein in its entirety.
  • Preferred siFVIIa molecules used in the present invention also include analogues of FVIIa in which one or more amino acids which are not present in the original sequence are added or deleted, and derivatives thereof.
  • the siFVIIa analogue exhibits an enhanced anticoagulant activity compared with the known siFVIIa proteins.
  • the analogue has a higher binding affinity for its binding partners, such as for example factor IX, X and/or TF, than the natural FVIIa.
  • the modifications result in a stabilization of the siFVIIa analogue.
  • SiFVIIa analogues can be used according to the present invention alone or in combination with other siFVIIa analogues and or homologues and/or derivatives and/or conjugates.
  • a siFVIIa analogue with a higher binding affinity for factor IX, X and/or TF can be used in combination with a stabilized siFVIIa homologue.
  • the siFVIIa molecule is an siFVIIa derivative.
  • siFVIIa derivative is defined as a molecule having the amino acid sequence of FVIIa or siFVIIa or of an FVIIa or siFVIIa analogue, but additionally comprises chemical modification of one or more of its amino acid side groups, alpha-carbon atoms, terminal amino group, or terminal carboxylic acid group.
  • a chemical modification includes, but is not limited to, adding chemical moieties, creating new bonds, and removing chemical moieties.
  • Modifications at amino acid side groups include, without limitation, acylation of lysine epsilon-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
  • Modifications of the terminal amino include, without limitation, the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications.
  • Modifications of the terminal carboxy group include, without limitation, the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. Lower alkyl is Cl—C4 alkyl.
  • one or more side groups, or terminal groups may be protected by protective groups known to the ordinarily-skilled protein chemist.
  • the alpha-carbon of an amino acid may be mono- or dimethylated.
  • a homologue of one or more of the sequences specified herein may vary in one or more amino acids as compared to the sequences defined, but is capable of performing the same function, i.e. a homologue may be envisaged as a functional equivalent of a predetermined sequence.
  • the siFVIIa molecule is a homologue of molecules disclosed herein, such as a homolog of any of the molecules selected from the group consisting of:
  • the siFVIIa molecule is a peptide containing one or more amino acid substitutions, inversion, additions and/or deletions, compared with molecules disclosed herein, such as a molecule selected from the group consisting of:
  • the number of substitutions, deletions, or additions is 20 amino acids or less, such as 15 amino acids or less, for example 10 amino acids or less, such as 9 amino acids or less, for example 8 amino acids or less, such as 7 amino acids or less, for example 6 amino acids or less, such as 5 amino acids or less, for example 4 amino acids or less, such as 3 amino acids or less, for example 2 amino acids or less (such as 1), or any integer in between these amounts.
  • the substitutions include one or more conservative substitutions, such as 20 or fewer conservative substitutions, for example 18 or fewer, such as 16 or fewer, for example 14 or fewer, such as 12 or fewer, for example 10 or fewer, such as 8 or fewer, for example 6 or fewer, such as 4 or fewer, for example 3 or fewer, such as 2 or fewer conservative substitutions.
  • a “conservative” substitution denotes the replacement of an amino acid residue by another, related amino acid residue belonging to the same group of amino acids, such as those with a hydrophobic side chain, those with an aromatic side chain, those with a basic side-chain, those with an acidic side chain, those with a hydroxyl side chain and those with a non-ionized polar side chain.
  • conservative substitution examples include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine or methionine for another, or the substitution of one basic residue for another, such as the substitution of arginine for lysine, or the substitution of one acidic residue for another, such as glutamic acid for aspartic acid, or the substitution of one non-ionized polar residue for another, such as the substitution of glutamine for asparagine, and the like.
  • the following table lists illustrative, but non-limiting, conservative amino acid substitutions.
  • siFVIIa homologues suitable for the uses and methods of the present invention are peptide sequences having greater than 50 percent sequence identity, and preferably greater than 90 percent sequence identity (such as greater than 91% sequence identity, for example greater than 92% sequence identity, such as greater than 93% sequence identity, for example greater than 94% sequence identity, such as greater than 95% sequence identity, for example greater than 96% sequence identity, such as greater than 97% sequence identity, for example greater than 98% sequence identity, such as greater than 99% sequence identity, for example greater than 99.5% sequence identity), to molecules disclosed herein, such as a molecule selected from the group consisting of:
  • sequence identity refers to a comparison made between two molecules using standard algorithms well known in the art.
  • the preferred algorithm for calculating sequence identity for the present invention is the Smith-Waterman algorithm, where the reference sequence is used to define the percentage identity of polypeptide homologs over its length.
  • the choice of parameter values for matches, mismatches, and inserts or deletions is arbitrary, although some parameter values have been found to yield more biologically realistic results than others.
  • One preferred set of parameter values for the Smith-Waterman algorithm is set forth in the “maximum similarity segments” approach, which uses values of 1 for a matched residue and ⁇ 1/3 for a mismatched residue (a residue being either a single nucleotide or single amino acid) (Waterman, Bull. Math. Biol. 46, 473-500 (1984)). Insertions and deletions (indels), x, are weighted as
  • k is the number of residues in a given insert or deletion (Id.).
  • truncations at the end of the molecule are not taken Into account when calculating sequence identity (i.e., if one molecule is longer than the other, only the overlapping lengths of the molecules are used in the sequence identity analysis); in another preferred embodiment of the present invention, truncations are counted as deletions.
  • a siFVIIa homologue may include D-amino acid forms and may be a molecule having one or more amino acid substitutions, deletions, inversions, or additions relative to molecules disclosed herein, such as a molecule selected from the group consisting of:
  • the siFVIIa molecule is a peptide containing one or more amino acid substitutions, inversion, additions or deletions, compared with FVIIa.
  • the number of substitutions, deletions, or additions is 20 amino acids or less, such as 15 amino acids or less, for example 10 amino acids or less, such as 9 amino acids or less, for example 8 amino acids or less such as 7 amino acids or less, for example 6 amino acids or less, such as 5 amino acids or less, for example 4 amino acids or less, such as 3 amino acids or less, for example 2 amino acids or less (such as 1), or any Integer in between these amounts.
  • the substitutions include one or more conservative substitutions. Examples of suitable conservative substitutions are given above.
  • siFVIIa homologues suitable for the uses and methods of the present invention are peptide sequences derived from protein C sequences having greater than 50 percent sequence identity, and preferably greater than 90 percent sequence identity (such as greater than 91% sequence identity, for example greater than 92% sequence identity, such as greater than 93% sequence identity, for example greater than 94% sequence identity, such as greater than 95% sequence identity, for example greater than 96% sequence identity, such as greater than 97% sequence identity, for example greater than 98% sequence identity, such as greater than 99% sequence identity, for example greater than 99.5% sequence identity), to (1) SEQ ID NO:1 and/or (2) to truncated sequences thereof.
  • sequence identity refers to a comparison made between two molecules using standard algorithms well known in the art.
  • the preferred algorithm for calculating sequence identity for the present invention is the Smith-Waterman algorithm, as described above.
  • siFVIIa homologue may also be a molecule having one or more amino acid substitutions, deletions, inversions, or additions relative to human FVIIa and may include D-amino acid forms.
  • said homologue of predetermined sequences herein, such as SEQ ID NO: 1 may be defined as:
  • siFVIIa molecules suitable for use in the present invention may be chemically derivatized or altered, for example, peptides with non-natural amino acid residues (e.g., taurine residue, beta- and gamma-amino acid residues and D-amino acid residues), C-terminal functional group modifications, such as amides, esters, and C-terminal ketone modifications and N-terminal functional group modifications, such as acylated amines, Schiff bases, or cyclization, such as found, for example, in the amino acid pyroglutamic acid.
  • non-natural amino acid residues e.g., taurine residue, beta- and gamma-amino acid residues and D-amino acid residues
  • C-terminal functional group modifications such as amides, esters
  • C-terminal ketone modifications such as acylated amines, Schiff bases, or cyclization, such as found, for example, in the amino acid pyroglutamic acid.
  • siFVIIa molecules of the present invention may also be modified with non-polypeptide moieties to yield siFVIIa compounds that have an increased resistance to inactivation by e.g. proteolytic degradation.
  • the siFVIIa molecule used is an N-glycosylated siFVIIa peptide or an analogue thereof.
  • the siFVIIa molecule is an O-glycosylated siFVIIa polypeptide or an analogue thereof.
  • the siFVIIa molecule used is a si FVIIa polypolypetide or an analogue thereof further containing and N-linked or O-linked fatty acid.
  • the siFVIIa molecule can be a siFVIIa fragment.
  • a fragment is a portion of siFVIIa, siFVIIa homologue or siFVIIa derivative.
  • fragments include EGF-like domains 1 or 2, EGF-like domains 1 and 2, the serine protease domain or deletions of the N-terminus or the C-terminus or both. Fragments of siFVIIa comprise at least 20 consecutive amino acids from SEQ ID NO: 1.
  • a fragment can be 20 amino acids or more, such as 25 amino acids or more, for example 30 amino acids or more, such as 50 amino acids or more, for example 100 amino acids or more, such as 150 amino acids or more, for example 200 amino acids or more, such as 250 amino acids or more, for example 275 amino acids in length or any integer in between these amounts.
  • Methods of administration include, but are not limited to, spraying, lavage, inhalation, flushing or installation, using as fluid a physiologically acceptable composition in which the blood coagulation factor or factors have been dissolved or suspended.
  • intratracheal, intrabronchial or intraalveolar administration include all forms of such administration whereby the coagulation factor is applied into the trachea, the bronchi or the alveoli, respectively, whether by the instillation of a solution of the factor, by applying the factor in a powder form, or by allowing the factor to reach the relevant part of the airway by inhalation of the factor as an aerosolized or nebulized solution or powder or gel, with or without added stabilizers or other excipients.
  • intratracheal, intrabronchial or intraalveolar administration does not include inhalation of the product but the instillation or application of a solution of the factor or a powder or a gel containing the factor into the trachea or lower airways.
  • Methods of intrabronchial/alveolar administration include, but are not limited to, bronchoalveolar lavage (BAL) administration according to methods well known to those skilled in the art, using as a lavage fluid a physiologically acceptable composition in which the siFVIIa and/or a siFVIIa homolog and/or derivative and/or conjugate has been dissolved, or indeed by any other effective form of intrabronchial administration including the use of nebulized powders containing the anticoagulant in dry form, with or without excipients, or the direct application of the anticoagulant in solution or powder or gel form during bronchoscopy.
  • BAL bronchoalveolar lavage
  • Methods of intratracheal administration include, but are not limited to, blind tracheal washing with a similar solution of dissolved or suspended site-inactivated FVIIa, or the inhalation of nebulized aerosolized fluid droplets containing the dissolved or suspended site-inactivated FVIIa obtained by use of any nebulizing apparatus adequate for this purpose.
  • the present invention provides a useful new addition to the methods of treating ALI, ARDS, pneumonia and other conditions associated with bronchoalveolar fibrin deposition.
  • the administration of the anticoagulants via the airway is expected to avoid the unwanted hemorrhagic adverse effects of systemic administration of anticoagulants such as siFVIIa, for example is the ex vivo use of ASIS associated with hemorrhagic risk.
  • the application of the anticoagulants via the airway is expected to potentiate their effect on extravascular fibrin deposition in the lungs, i.e. in the alveoli when compared with their systemic administration, by which route adverse effects such as bleeding complicated may be serious.
  • an anticoagulant and anti-inflammatory agent such as siFVIIa may be used alone locally within the airspaces or may be divided between the conventional intravenous route and the airway route of the present invention to obtain the optimal balance between the systemic and local pulmonary effects of the treatment, and a reduced incidence of drug adverse effect, for example in patients with severe sepsis, septic shock and ARDS.
  • the time interval (“window of opportunity”) during which the intravenous use of siFVIIa is likely to be beneficial is limited, most likely to the very early phase of the development of a clinical significant ARDS condition.
  • a longer time interval of drug response may be expected when the agent is used in the later ARDS phase, e.g. in post-septic phase or even in the late ARDS phase dominated by alveolar fibrin deposition, e.g. as seen in ALI and ARDS.
  • a preferred embodiment of the present invention comprises local intrabronchial administration to human patients with ARDS of siFVIIa by means of bronchoalveolar lavage with lavage fluid, e.g. 25 ml to 100 ml of isotonic saline, in which a suitable dose (e.g. 2 mg to 5 mg or more) of siFVIIa has been dissolved.
  • lavage fluid e.g. 25 ml to 100 ml of isotonic saline
  • a suitable dose e.g. 2 mg to 5 mg or more
  • siFVIIa can also be given by intravenous infusion.
  • the aerosol or powder may be delivered by via a) facemasks or b) via endotracheal tubes in intubated patients during mechanical ventilation (device 1, 2 and 3).
  • the devices 4 and 5 can also be used by the patient without assistance provided that the patient is able to self-activate the aerosol or powder device.
  • Preferred concentrations for a solution comprising siFVIIa and/or homologues and/or derivatives of siFVIIa are in the range of 0.1 ⁇ g to 10000 ⁇ g active ingredient per ml solution.
  • the suitable concentrations are often in the range of from 0.1 ⁇ g to 5000 ⁇ g per ml solution, such as in the range of from about 0.1 ⁇ g to 3000 ⁇ g per ml solution, and especially in the range of from about 0.1 ⁇ g to 1000 ⁇ g per ml solution, such as in the range of from about 0.1 ⁇ g to 250 ⁇ g per ml solution.
  • a preferred concentration would be from about 0.1 to about 5.0 mg, preferably from about 0.3 mg to about 3.0 mg, such as from about 0.5 to about 1.5 mg and especially in the range from 0.8 to 1.0 mg per ml solution.
  • the suitable concentrations are often in the range of from 0.1 ⁇ g to 1000 ⁇ g per ml solution, such as in the range of from about 0.1 ⁇ g to 750 ⁇ g per ml solution, and especially in the range of from about 0.1 ⁇ g to 500 ⁇ g per ml solution, such as in the range of from about 0.1 ⁇ g to 250 ⁇ g per ml solution.
  • a preferred concentration would be from about 0.1 to about 5.0 mg, preferably from about 0.3 mg to about 3.0 mg, such as from about 0.5 to about 1.5 mg and especially in the range from 0.8 to 1.0 mg per ml solution.
  • One aspect of the present invention relates to a method of treating or preventing extravascular fibrin deposition in the airways.
  • the present invention relates to the treatment of individuals suffering from, or at risk of suffering from, extravascular fibrin depositions caused by an inflammatory lung disease.
  • the inflammatory lung disease is selected from the group consisting of:
  • the inflammatory lung disease is related to a condition selected from the group consisting of:
  • compositions or formulations for use in the present invention include an siFVIIa preparation in combination with, preferably dissolved or suspended in, a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluent.
  • a pharmaceutically acceptable carrier preferably an aqueous carrier or diluent.
  • the pharmaceutical composition may be a solid, a liquid, a gel, powder or an aerosol.
  • a variety of aqueous carriers may be used, such as 0.9% saline, buffered saline, physiologically compatible buffers and the like.
  • the compositions may be sterilized by conventional techniques well known to those skilled in the art.
  • the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and freeze-dried, the freeze-dried preparation being dissolved or suspended in a sterile aqueous solution prior to administration.
  • compositions may contain pharmaceutically acceptable auxiliary substances or adjuvants, including, without limitation, pH adjusting and buffering agents and/or tonicity adjusting agents, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
  • the formulations may contain pharmaceutically acceptable carriers and excipients including microspheres, liposomes, microcapsules, nanoparticles or the like.
  • Conventional liposomes are typically composed of phospholipids (neutral or negatively charged) and/or cholesterol.
  • the liposomes are vesicular structures based on lipid bilayers surrounding aqueous compartments.
  • lipids bilayers can vary in their physiochemical properties such as size, lipid composition, surface charge and number and fluidity of the phospholipids bilayers.
  • the most frequently used lipid for liposome formation are: 1,2-Dilauroyl-sn-Glycero-3-Phosphocholine (DLPC), 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC), 1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC), 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC), 1,2-Dimyristoyl-sn-Glycero-3-Phosphoethanolamine (DMPE), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), 1,2-Dioleoyl
  • Long-circulating liposomes are characterized by their ability to extravasate at body sites where the permeability of the vascular wall is increased.
  • the most popular way of producing long-circulating liposomes is to attach hydrophilic polymer polyethylene glycol (PEG) covalently to the outer surface of the liposome.
  • PEG polyethylene glycol
  • lipids are: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000] (Ammonium Salt), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-5000] (Ammonium Salt), 1,2-Dioleoyl-3-Trimethylammonium-Propane (Chloride Salt) (DOTAP).
  • the liposome suspension may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damage on storage.
  • Lipophilic free-radical quenchers such as alpha-tocopherol and water-soluble iron-specific chelators, such as ferrioxianine, are preferred.
  • the film may be redissolved or suspended in a suitable solvent, such as tertiary butanol, and then lyophilized to form a more homogeneous lipid mixture which is in a more easily hydrated powder-like form.
  • a suitable solvent such as tertiary butanol
  • This film is covered with an aqueous solution of the targeted drug and the targeting component and allowed to hydrate, typically over a 15-60 minute period with agitation.
  • the size distribution of the resulting multilamellar vesicles can be shifted toward smaller sizes by hydrating the lipids under more vigorous agitation conditions or by adding solubilizing detergents such as deoxycholate.
  • Micelles are formed by surfactants (molecules that contain a hydrophobic portion and one or more ionic or otherwise strongly hydrophilic groups) in aqueous solution.
  • Suitable surfactants include sodium laureate, sodium oleate, sodium lauryl sulfate, octaoxyethylene glycol monododecyl ether, octoxynol 9 and PLURONIC F-127 (Wyandotte Chemicals Corp.).
  • Preferred surfactants are nonionic polyoxyethylene and polyoxypropylene detergents compatible with IV injection such as, TWEEN-80, PLURONIC F-68, n-octyl-beta-D-glucopyranoside, and the like.
  • phospholipids such as those described for use in the production of liposomes, may also be used for micelle formation.
  • the preparations are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective.
  • the quantity to be administered depends on the subject to be treated, including, e.g. the weight and age of the subject, the disease to be treated and the stage of disease. Suitable dosage ranges are per kilo body weight normally of the order of several hundred ⁇ g active ingredient per administration with a preferred range of from about 0.1 ⁇ g to 10000 ⁇ g per kilo body weight.
  • the suitable dosages are often in the range of from 0.1 ⁇ g to 5000 ⁇ g per kilo body weight, such as in the range of from about 0.1 ⁇ g to 3000 ⁇ g per kilo body weight, and especially in the range of from about 0.1 ⁇ g to 1000 ⁇ g per kilo body weight.
  • the suitable dosages are often in the range of from 0.1 ⁇ g to 1000 ⁇ g per kilo body weight, such as in the range of from about 0.1 ⁇ g to 750 ⁇ g per kilo body weight, and especially in the range of from about 0.1 ⁇ g to 500 ⁇ g per kilo body weight such as in the range of from about 0.1 ⁇ g to 250 ⁇ g per kilo body weight.
  • a preferred dosage would be from about 0.1 to about 5.0 mg, preferably from about 0.3 mg to about 3.0 mg, such as from about 0.5 to about 1.5 mg and especially in the range from 0.8 to 1.0 mg per administration. Administration may be performed once or may be followed by subsequent administrations. The dosage will also depend on the route of administration and will vary with the age, sex and weight of the subject to be treated.
  • a preferred dosage of multimeric forms would be in the interval 1 mg to 70 mg per 70 kilo body weight.
  • Suitable daily dosage ranges are per kilo body weight per day normally of the order of several hundred ⁇ g active ingredient per day with a preferred range of from about 0.1 ⁇ g to 10000 ⁇ g per kilo body weight per day.
  • the suitable dosages are often in the range of from 0.1 ⁇ g to 5000 ⁇ g per kilo body weight per day, such as in the range of from about 0.1 ⁇ g to 3000 ⁇ g per kilo body weight per day, and especially in the range of from about 0.1 ⁇ g to 1000 ⁇ g per kilo body weight per day.
  • the suitable dosages are often in the range of from 0.1 ⁇ g to 1000 ⁇ g per kilo body weight per day, such as in the range of from about 0.1 ⁇ g to 750 ⁇ g per kilo body weight per day, and especially in the range of from about 0.1 ⁇ g to 500 ⁇ g per kilo body weight per day, such as in the range of from about 0.1 ⁇ g to 250 ⁇ g per kilo body weight per day.
  • a preferred dosage would be from about 0.1 to about 100 ⁇ g, preferably from about 0.1 ⁇ g to about 50 ⁇ g, such as from about 0.3 to about 30 ⁇ g and especially in the range from 1.0 to 10 ⁇ g per kilo body weight per day.
  • Administration may be performed once or may be followed by subsequent administrations.
  • the dosage will also depend on the route of administration and will vary with the age, sex and weight of the subject to be treated.
  • a preferred dosage of multimeric forms would be in the interval 1 mg to 70 mg per 70 kilo body weight per day.
  • the compounds used in the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
  • the formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art.
  • kits typically contains an active compound in dosage forms for administration.
  • a dosage form contains a sufficient amount of active compound such that a desirable effect can be obtained when administered to a subject.
  • the medical packaging comprises an amount of dosage units corresponding to the relevant dosage regimen.
  • the medical packaging comprises a pharmaceutical composition comprising a compound as defined above or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carriers, vehicles and/or excipients, said packaging comprising from 1 to 7 dosage units, thereby having dosage units for one or more days, or from 7 to 21 dosage units, or multiples thereof, thereby having dosage units for one week of administration or several weeks of administration.
  • the dosage units can be as defined above.
  • the medical packaging may be in any suitable form for intratracheal, intrabronchial or intraalveolar administration.
  • the packaging is in the form of a vial, ampule, tube, blister pack, cartridge or capsule.
  • the medical packaging comprises more than one dosage unit
  • the medical packaging is provided with a mechanism to adjust each administration to one dosage unit only.
  • kits contains instructions indicating the use of the dosage form to achieve a desirable affect and the amount of dosage form to be taken over a specified time period.
  • the medical packaging comprises instructions for administering the pharmaceutical composition.
  • ARDS Patients with ventilator associated pneumonia secondary to bacterial Strep. pneumonia, Pneumocystis Carinii pneumonia (PCP) or other types of pneumonia or ARDS secondary to sepsis, Disseminated intravascular coagulation (DIC), trauma, pulmonary aspiration pneumonitis, severe pancreatitis or bleomycin induced ARDS with ongoing treatment with mechanical ventilation, with development of ARDS with reduced oxygenation capacity as revealed by a reduced PaO 2 /FiO 2 ratio, i.e. ⁇ 200 mmHg (arterial oxygen tension in mmHg over inspired oxygen fraction) in spite of treatment with full antibiotic coverage towards the isolated microbiological agent or treatment of underlying disease.
  • PaO 2 /FiO 2 ratio i.e. ⁇ 200 mmHg (arterial oxygen tension in mmHg over inspired oxygen fraction) in spite of treatment with full antibiotic coverage towards the isolated microbiological agent or treatment of underlying disease.
  • a successful treatment results in an increase in oxygen capacity with a PaO 2 /FiO 2 ratio, i.e. >200 mmHg.
  • Radiography of the lung field before and after treatment As the patients have infiltrations in the lung a successful treatment leads to reduction of these infiltrations as monitored by radiography.
  • ARDS Patients with ventilator associated pneumonia secondary to bacterial Strep. Pneumonia, Pneumocystis Carinii pneumonia or other types of pneumonia or ARDS secondary to sepsis, Disseminated intravascular coagulation (DIC), trauma or pulmonary aspiration pneumonitis or severe pancreatitis or or bleomycin induced ARDS with ongoing treatment with mechanical ventilation, with development of ARDS with reduced oxygenation capacity as revealed by a reduced PaO 2 /FiO 2 ratio, i.e. ⁇ 200 mmHg (arterial oxygen tension in mmHg over inspired oxygen fraction) in spite of treatment with full antibiotic coverage towards the isolated microbiological agent or treatment of underlying disease.
  • PaO 2 /FiO 2 ratio i.e. ⁇ 200 mmHg (arterial oxygen tension in mmHg over inspired oxygen fraction) in spite of treatment with full antibiotic coverage towards the isolated microbiological agent or treatment of underlying disease.
  • a successful treatment results in an increase in oxygen capacity with a PaO 2 /FiO 2 ratio, i.e. >200 mmHg.
  • Radiography of the lung field before and after treatment As the patients have infiltrations in the lung a successful treatment leads to reduction of these infiltrations as monitored by radiography.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
US11/993,264 2005-06-24 2006-06-23 Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract Abandoned US20100279925A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/993,264 US20100279925A1 (en) 2005-06-24 2006-06-23 Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002631 WO2006136963A2 (fr) 2005-06-24 2006-06-23 Administration par voie aerienne de fviia a site inactive dans des conditions inflammatoires affectant les voies respiratoires
US11/993,264 US20100279925A1 (en) 2005-06-24 2006-06-23 Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract

Publications (1)

Publication Number Publication Date
US20100279925A1 true US20100279925A1 (en) 2010-11-04

Family

ID=37570814

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/993,264 Abandoned US20100279925A1 (en) 2005-06-24 2006-06-23 Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract
US11/993,253 Expired - Fee Related US8088728B2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
US11/993,256 Abandoned US20100297099A1 (en) 2005-06-24 2006-06-23 Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/993,253 Expired - Fee Related US8088728B2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
US11/993,256 Abandoned US20100297099A1 (en) 2005-06-24 2006-06-23 Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract

Country Status (15)

Country Link
US (3) US20100279925A1 (fr)
EP (3) EP1898945B1 (fr)
JP (3) JP2008543925A (fr)
KR (2) KR20080074085A (fr)
CN (2) CN101262880A (fr)
AU (2) AU2006273696B2 (fr)
BR (2) BRPI0613137A2 (fr)
CA (2) CA2612646C (fr)
DK (3) DK1898945T3 (fr)
HK (1) HK1114567A1 (fr)
IL (2) IL188220A0 (fr)
NO (2) NO20080434L (fr)
RU (2) RU2496516C2 (fr)
WO (3) WO2007012976A2 (fr)
ZA (2) ZA200800255B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007331874B2 (en) * 2006-12-11 2012-10-11 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
CA2946028C (fr) * 2014-04-16 2022-10-11 Zz Biotech Llc Traitement de cicatrices cutanees anormales
CA2946032C (fr) 2014-04-16 2022-06-14 Zz Biotech Llc Utilisation d'analoge d'apc pour la cicatrisation des plaies
US20190269765A1 (en) * 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4784950A (en) * 1985-04-17 1988-11-15 Zymogenetics, Inc. Expression of factor VII activity in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5731346A (en) * 1992-02-24 1998-03-24 Pharmacia & Upjohn Aktiebolag Use of omega-3-fatty acids
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
US6806063B2 (en) * 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
US6974800B1 (en) * 1999-05-03 2005-12-13 Astrazeneca Ab Formulations comprising an inhibitor of carboxypeptidase U and A thrombin inhibitor
US7189289B2 (en) * 2002-02-08 2007-03-13 Sk Corporation Cleaning agent and method for cleaning heater tubes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
EP0946715B1 (fr) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Utilisation d'une proteine c modifiee
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
WO2001057193A2 (fr) * 2000-02-02 2001-08-09 Eli Lilly And Company Derives de proteine c
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP2004527554A (ja) * 2001-05-02 2004-09-09 ノボ　ノルディスク　アクティーゼルスカブ Ａｒｄｓの処理における修飾されたｆｖｉｉ
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
WO2003032904A2 (fr) * 2001-10-15 2003-04-24 Chiron Corporation Traitement de la pneumonie grave par administration d'un inhibiteur du mecanisme d'action du facteur tissulaire (tfpi)
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (fr) * 2003-11-04 2005-05-12 Novo Nordisk A/S Composition pharmaceutique contenant un polypeptide de proteine c et un regulateur de glucose sanguin
CA2579884C (fr) * 2004-09-10 2013-12-31 Pharmaorigin Aps Procede pour traiter les saignements locaux tracheaux, bronchiques ou alveolaires ou l'hemoptysie
JP2008515908A (ja) 2004-10-06 2008-05-15 ユニバーシティー オブ ロチェスター 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4784950A (en) * 1985-04-17 1988-11-15 Zymogenetics, Inc. Expression of factor VII activity in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5731346A (en) * 1992-02-24 1998-03-24 Pharmacia & Upjohn Aktiebolag Use of omega-3-fatty acids
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
US6974800B1 (en) * 1999-05-03 2005-12-13 Astrazeneca Ab Formulations comprising an inhibitor of carboxypeptidase U and A thrombin inhibitor
US6806063B2 (en) * 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
US7189289B2 (en) * 2002-02-08 2007-03-13 Sk Corporation Cleaning agent and method for cleaning heater tubes

Also Published As

Publication number Publication date
EP1898945A2 (fr) 2008-03-19
US20100160218A1 (en) 2010-06-24
US20100297099A1 (en) 2010-11-25
EP1906994B1 (fr) 2014-04-23
EP1906994A2 (fr) 2008-04-09
RU2008102656A (ru) 2009-07-27
CA2612597A1 (fr) 2007-02-01
ZA200800251B (en) 2009-04-29
RU2496515C2 (ru) 2013-10-27
JP2013151510A (ja) 2013-08-08
WO2007012976A3 (fr) 2007-07-12
AU2006260599A1 (en) 2006-12-28
IL188221A0 (en) 2008-03-20
CA2612646C (fr) 2015-11-24
IL188220A0 (en) 2008-03-20
BRPI0611710A2 (pt) 2011-12-20
WO2006136963A2 (fr) 2006-12-28
EP1898945B1 (fr) 2012-12-19
RU2496516C2 (ru) 2013-10-27
KR20080074085A (ko) 2008-08-12
DK1896059T3 (da) 2013-04-08
WO2006136963A3 (fr) 2007-07-12
CN101262880A (zh) 2008-09-10
JP2008543925A (ja) 2008-12-04
CA2612597C (fr) 2015-03-31
WO2007012976A2 (fr) 2007-02-01
AU2006273696A1 (en) 2007-02-01
CA2612646A1 (fr) 2006-12-28
EP1896059B1 (fr) 2012-12-19
WO2006136962A2 (fr) 2006-12-28
WO2006136962A3 (fr) 2007-07-12
DK1898945T3 (da) 2013-03-25
US8088728B2 (en) 2012-01-03
BRPI0613137A2 (pt) 2010-12-21
NO20080433L (no) 2008-03-19
HK1114567A1 (en) 2008-11-07
ZA200800255B (en) 2009-04-29
AU2006273696B2 (en) 2012-08-30
CN101262879A (zh) 2008-09-10
EP1896059A2 (fr) 2008-03-12
DK1906994T3 (da) 2014-07-21
RU2008102655A (ru) 2009-07-27
KR20080071116A (ko) 2008-08-01
CN101262879B (zh) 2013-04-10
JP2008543926A (ja) 2008-12-04
NO20080434L (no) 2008-03-17

Similar Documents

Publication Publication Date Title
JP6001151B2 (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
EP1898945B1 (fr) Administration par voie aerienne de fviia a site inactive dans des conditions inflammatoires affectant les voies respiratoires
US20150174204A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
MX2007016370A (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
WO2015110536A1 (fr) Facteur de stimulation des colonies de granulocytes et macrophages pour le traitement et la prévention de formes graves de l'asthme bronchique

Legal Events

Date Code Title Description
AS Assignment

Owner name: DRUGRECURE APS, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UTTENTHAL, LARS OTTO;REEL/FRAME:020494/0618

Effective date: 20080129

AS Assignment

Owner name: HOIBERG A/S, DENMARK

Free format text: CERTIFICATE OF DEBT;ASSIGNORS:PHARMAORIGIN APS;DRUGRECURE APS;REEL/FRAME:026036/0955

Effective date: 20110324

AS Assignment

Owner name: HOIBERG A/S, DENMARK

Free format text: CORRECTIVE CERTIFICATE OF DEBT AND AGREEMENT;ASSIGNORS:PHARMAORIGIN APS;DRUGRECURE APS;REEL/FRAME:026126/0130

Effective date: 20110324

AS Assignment

Owner name: DRUGRECURE APS, DENMARK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:HOIBERG A/S;REEL/FRAME:032864/0284

Effective date: 20140307

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载